Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 1:00 pm Purchase |
2022-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
Flagship VentureLabs IV LLC | 38,606,526 42.700% |
38,606,526 (New Position) |
Filing History |
| 2022-10-17 4:32 pm Purchase |
2022-10-13 | 13D | Axcella Health Inc. AXLA |
Flagship VentureLabs IV LLC | 1,170,062 39.800% |
415,350 (+55.03%) |
Filing History |
| 2022-09-23 4:31 pm Unchanged |
2022-09-20 | 13D | Axcella Health Inc. AXLA |
Flagship VentureLabs IV LLC | 754,711 35.800% |
0 (Unchanged) |
Filing History |
| 2022-07-07 5:00 pm Purchase |
2022-07-05 | 13D | Seres Therapeutics, Inc. MCRB |
Flagship VentureLabs IV LLC | 23,493,063 18.900% |
8,443,072 (+56.10%) |
Filing History |
| 2022-03-18 08:30 am Purchase |
2022-03-16 | 13D | Axcella Health Inc. AXLA |
Flagship VentureLabs IV LLC | 754,711 36.400% |
252,775 (+50.36%) |
Filing History |
| 2020-11-25 4:30 pm Sale |
2020-11-23 | 13D | Seres Therapeutics, Inc. MCRB |
Flagship VentureLabs IV LLC | 15,049,991 16.500% |
-6,596,914 (-30.48%) |
Filing History |
| 2020-05-20 5:00 pm Purchase |
2020-05-18 | 13D | Axcella Health Inc. AXLA |
Flagship VentureLabs IV LLC | 501,937 35.000% |
152,000 (+43.44%) |
Filing History |